香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zhong Jia Guo Xin Holdings Company Limited 中加國信控股股份有限公司 （於百慕達註冊成立之有限公司） （股份代號：899） 自願性公告 業務最新情況 本公告乃由中加國信控股股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願公佈，旨在向本公司股東（「股東」）及潛在投資者提供本集團最新業務發展情況。 本公司董事（「董事」）會（「董事會」）謹此通知根據截至二零二五年三月三十一日止年 度的年度報告，集團曾於二零二四年四月一日作出預測（「預測」），預期截至二零二五年 三月三十一日止年度將實現租金收入約1027萬港元及礦產銷售約1302萬港元。而實際該年度 租金收入約755萬港元，礦產銷售為0港元，較預測值分別出現約29.57%（「租金差額」）及 100%（「礦產差額」）的差額（統稱「差額」）。 公司本預期，在新冠疫情限制措施解除後，中國經濟將在2024年有所好 ...

Summary of Pfizer's Conference Call Company Overview - **Company**: Pfizer Inc. - **Date**: August 6, 2025 Key Industry Insights - **Strategic Focus**: Pfizer's 2025 strategy emphasizes enhancing R&D productivity through workforce and process streamlining, leveraging technology and AI for operational optimization. The company anticipates cumulative cost savings of $7.7 billion by the end of 2027, aimed at improving business profitability [2][18][19]. Core Product Performance - **Eliquis**: Strong market performance, particularly in the UK and Spain, with significant growth noted. In initial treatment for third-line indications, the median overall survival exceeds 2 years, more than double historical figures [2][5]. - **Keytruda**: Demonstrated a total response rate exceeding 97% in newly diagnosed multiple myeloma patients when administered as a subcutaneous fixed-dose regimen, with controllable safety [2][5]. R&D Developments - **Non-Small Cell Lung Cancer**: Advancements in the development of a beta6abc integrin inhibitor, with a confirmed response rate of 31% in second-line populations and a 57% response rate in first-line treatment patients [2][6]. - **Hemophilia Treatment**: Introduction of a subcutaneous self-injector for hemophilia A or B, achieving a 93% reduction in annual bleeding rates, outperforming approved products [2][7][8]. - **Vaccine Candidates**: A second-generation vaccine candidate shows 100% efficacy against difficult infections, currently in Phase II trials, with plans for Phase III trials. A Lyme disease vaccine candidate is expected to submit for approval next year [2][9]. Financial Performance - **Q2 2025 Results**: Pfizer reported revenues of $14.7 billion, a 10% year-over-year increase. Adjusted diluted EPS was $0.78, exceeding expectations. The company maintains a full-year revenue outlook of $61 billion to $64 billion [3][4][17]. - **Cost Management**: Pfizer achieved an 8% reduction in adjusted operating expenses, with R&D expenses down 9%. The first phase of manufacturing optimization is expected to yield $1.5 billion in savings [18]. Market Position and Competitive Strategy - **BMS-Pfizer Alliance**: The alliance holds a 47% market share in the oral CDRP category, enhancing competitiveness through customized dosing options and expanded channels [4][12]. - **International Market Growth**: Strong performance in international markets, with a 32% increase in patient treatment volumes, and a 50% increase year-to-date [35][36]. Future Outlook - **Business Development**: Pfizer plans to pursue smaller-scale transactions to achieve a $1-1.5 billion capacity target, with a focus on oncology, vaccines, and internal medicine [21][28]. - **Regulatory Environment**: The company is actively engaging with U.S. government entities regarding competitive pressures from Chinese biotechnology firms and is preparing for potential impacts from proposed trade and tariff policies [29][30][37]. Additional Considerations - **Vaccine Uptake**: Changes in CDC vaccine recommendations may impact vaccination rates, but Pfizer anticipates a strong upcoming season due to robust supply and distribution capabilities [20]. - **Capital Allocation**: Pfizer's capital allocation strategy remains cautious, focusing on pipeline execution and operational efficiency [47]. This summary encapsulates the key points from Pfizer's conference call, highlighting the company's strategic initiatives, product performance, financial results, and future outlook in the pharmaceutical industry.

Fundraising Plan - The company plans to raise a total of 956,340,000.00 yuan through a private placement, with the net proceeds to be used entirely for debt repayment and to supplement working capital [1][2] Necessity and Feasibility Analysis - The necessity of the fundraising is highlighted by the company's significant debt, totaling approximately 1.512 billion yuan, with a high asset-liability ratio of 85.75% as of the end of 2024. The current cash balance of 118 million yuan is insufficient to cover these debts [1][2] - The feasibility of the fundraising is supported by its alignment with relevant policies and regulations, as well as the company's operational needs. The funds will help optimize the capital structure and enhance debt repayment capacity [2][3] Impact on Financial Status and Management - The fundraising is expected to positively impact the company's financial status by significantly increasing total assets and net assets, thereby improving the asset structure and reducing the asset-liability ratio [3][4] - The funds will alleviate debt pressure, enhance financial stability, and support ongoing business operations and product innovation, ultimately improving competitiveness and profitability [2][4] Governance and Fund Management - The company has established a governance structure in line with listing standards, ensuring independent operation of the board and management. A fundraising management system is in place to oversee the use of raised funds [3][4]

Core Viewpoint - Jiangsu Huasheng Lithium Battery Materials Co., Ltd. is planning to change its business scope and amend its Articles of Association, which will be submitted for approval at the shareholders' meeting [1][3]. Business Scope Change - The company intends to expand its business scope to include the production and operation of hazardous chemicals, which requires approval from relevant authorities before commencement [1][2]. - The original business scope included battery components production and sales, specialized chemical products manufacturing (excluding hazardous chemicals), and various technical services [1]. - The revised business scope maintains the original items while adding the production and operation of hazardous chemicals as a licensed project [2]. Amendments to Articles of Association - The amendments to the Articles of Association reflect the changes in the business scope, specifically adding hazardous chemicals production and operation as licensed projects [2]. - Other provisions of the Articles of Association will remain unchanged [3]. Next Steps - The company will seek authorization from the shareholders' meeting to allow management to adjust the content based on the specific review requirements of the regulatory authorities [4]. - Following the shareholders' approval, the company will proceed with the necessary business registration changes and issue a new business license [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Lesi Group Limited 樂 思 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：2540） 自願公告 業務發展最新進展 本 公 告 乃 由 樂 思 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出。 本 公 司 董 事（「董 事」，各 為 一 名「董 事」）會（「董事會」）宣 佈，於 二 零 二 五 年 一 月， 本 公 司 之 全 資 附 屬 公 司 北 京 樂 思 創 信 科 技 有 限 公 司（「北京樂思創信」）與 廈 門 今 日 頭 條 信 息 技 術 有 限 公 司（「今日頭條」）及 重 慶 懂 車 族 科 技 有 限 公 司（「懂車族」） 訂 立 一 份 保 證 ...